{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T12:05:22Z","timestamp":1780920322268,"version":"3.54.1"},"reference-count":25,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To establish a UK consensus vision of a standardised genomic testing pathway in unresectable\/metastatic urothelial cancer (mUC) with clear roles and responsibilities for multidisciplinary team (MDT) members and molecular pathology laboratory teams, and to agree how the pathway must evolve to accommodate emerging innovations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Subjects and Methods<\/jats:title>\n                    <jats:p>A modified Delphi method was used. Six healthcare professionals (HCPs) with expertise in UC formed the Steering Committee (SC), which met in May 2025. Seven key consensus topics were developed covering the steps of the pre\u2010testing and genomic testing pathways, the current and future state of precision medicine, and approaches to overcome barriers and ensure readiness for the future. Within these topics, statements were developed and distributed to clinical scientists and HCPs via an on\u2010line 4\u2010point Likert scale survey. Respondents could opt out of responding to statements outside their area of expertise. Consensus was pre\u2010defined as \u226575% agreement.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 50 responses were received; consensus was reached on 41\/42 statements. The statement that did not achieve consensus was part of a paired set. A proposed pathway for pre\u2010testing and genomic testing in unresectable or mUC was developed based on survey results and discussions at SC meetings. Key priorities for the pathway include: timely fibroblast growth factor receptor 3 testing, ideally at the commencement of first\u2010line systemic therapies; selection of specimens based on volume of tissue and recency; immediate access to the genomic testing report for all MDT members; and secure data environments with federated access to genomic results. Since the stopping criteria were met, no further survey rounds were required.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Adopting the genomic testing pathway derived from this Delphi consensus will provide greater clarity around MDT and molecular laboratory responsibilities, reduce regional inequities in access, and optimise patient outcomes through timely delivery of genomic testing and subsequent treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/bju.70278","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T09:08:54Z","timestamp":1777280934000},"page":"144-155","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Delphi consensus for implementing genomic testing in unresectable or metastatic urothelial cancer"],"prefix":"10.1111","volume":"138","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1552-511X","authenticated-orcid":false,"given":"Syed A.","family":"Hussain","sequence":"first","affiliation":[{"name":"Division of Clinical Medicine, School of Medicine and Population Health University of Sheffield and Sheffield Teaching Hospitals  Sheffield UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amarnath","family":"Challapalli","sequence":"additional","affiliation":[{"name":"Bristol Cancer Institute  Bristol UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simran","family":"Gill","sequence":"additional","affiliation":[{"name":"Johnson and Johnson Innovative Medicine  High Wycombe UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hubank","sequence":"additional","affiliation":[{"name":"Royal Marsden Hospital  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1877-6056","authenticated-orcid":false,"given":"Hannah","family":"Markham","sequence":"additional","affiliation":[{"name":"University Hospital Southampton  Southampton UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Tani\u00e8re","sequence":"additional","affiliation":[{"name":"Queen Elizabeth Hospital  Birmingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Wyatt","sequence":"additional","affiliation":[{"name":"Johnson and Johnson Innovative Medicine  High Wycombe UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Jones","sequence":"additional","affiliation":[{"name":"University of Glasgow Beatson West of Scotland Cancer Centre  Glasgow UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,4,27]]},"reference":[{"key":"e_1_2_13_2_1","unstructured":"Cancer Research UK.Early cancer diagnosis data hub [Internet].2025. Available at:https:\/\/crukcancerintelligence.shinyapps.io\/EarlyDiagnosis\/_w_0fec2ef1e0ff482d8327fde5f49477d1\/?Tab=hometab. Accessed October 2025"},{"key":"e_1_2_13_3_1","unstructured":"Cancer Research UK.Types of bladder cancer [Internet].2025. Available at:https:\/\/www.cancerresearchuk.org\/about\u2010cancer\/bladder\u2010cancer\/types\u2010stages\u2010grades\/types. Accessed July 2025"},{"key":"e_1_2_13_4_1","volume-title":"EAU guidelines on muscle\u2010invasive and metastatic bladder cancer","author":"Heijden AG","year":"2025"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15194886"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2024.39.e320"},{"key":"e_1_2_13_7_1","unstructured":"NHS.National genomic test directory for cancer (v.13.1).2025. Available at:https:\/\/www.england.nhs.uk\/publication\/national\u2010genomic\u2010test\u2010directories\/. Accessed July 2025"},{"key":"e_1_2_13_8_1","volume-title":"Bladder cancer: diagnosis and management (NG2)","author":"NICE","year":"2015"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.11.012"},{"key":"e_1_2_13_10_1","unstructured":"Canadian Agency for Drugs and Technologies in Health.Reimbursement recommendation \u2010 erdafitinib (balversa). Ottawa (Canada).2025Report No. PC0375"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.69613\/kqjwcv45"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111859"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2021.02.008"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1601827113"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-094343"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1004326"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2013.12.002"},{"key":"e_1_2_13_18_1","unstructured":"NHS England.Genomic laboratory hubs [Internet].2025. Available at:https:\/\/www.england.nhs.uk\/genomics\/genomic\u2010laboratory\u2010hubs\/. Accessed October 2025"},{"key":"e_1_2_13_19_1","unstructured":"NHS England.Genomic testing in the devolved nations [Internet].2025. Available at:https:\/\/www.genomicseducation.hee.nhs.uk\/genotes\/knowledge\u2010hub\/genomic\u2010testing\u2010in\u2010the\u2010devolved\u2010nations\/. Accessed October 2025"},{"key":"e_1_2_13_20_1","volume-title":"Fit for the future: 10 year health plan for England","author":"UK Government","year":"2025"},{"key":"e_1_2_13_21_1","unstructured":"Scottish Government.Person\u2010centred care: advice for non\u2010executive board members [Internet].2019. Available at:https:\/\/www.gov.scot\/publications\/person\u2010centred\u2010care\u2010non\u2010executive\u2010members\/. Accessed October 2025"},{"key":"e_1_2_13_22_1","first-page":"19","article-title":"The genetic architecture of bone metastases: unveiling the role of epigenetic and genetic modifications in drug resistance","volume":"8","author":"Dawalibi A","year":"2025","journal-title":"Cancer Drug Resist"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK-25-471912"},{"key":"e_1_2_13_24_1","unstructured":"JonesL.100 000 Genomes Project \u2010 Cancer sample quality [Internet].2016. Available at:https:\/\/www.acgs.uk.com\/media\/10640\/0930_\u2010_02_\u2010_cancer_sample_quality_louise_jones__barts_ascg_2016.pdf. Accessed October 2025"},{"key":"e_1_2_13_25_1","volume-title":"Enfortumab vedotin with pembrolizumab for untreated unresectable or metastatic urothelial cancer when platinum\u2010based chemotherapy is suitable (TA1097)","author":"NICE","year":"2025"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/GO.23.00244"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bju.70278","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bju.70278","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bju.70278","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T11:29:32Z","timestamp":1780918172000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/bju.70278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,27]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1111\/bju.70278"],"URL":"https:\/\/doi.org\/10.1111\/bju.70278","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,27]]},"assertion":[{"value":"2026-04-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}